Article
Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
Molecular cancer therapeutics - 1 Feb 2015
Osman Abdullah A, Monroe Marcus M, Ortega Alves Marcus V, Patel Ameeta A, Katsonis Panagiotis, Fitzgerald Alison L, Neskey David M, Frederick Mitchell J, Woo Sang Hyeok, Caulin Carlos, Hsu Teng-Kuei, McDonald Thomas O, Kimmel Marek, Meyn Raymond E, Lichtarge Olivier, Myers Jeffrey N
Abstract excerpt
Although cisplatin has played a role in "standard-of-care" multimodality therapy for patients with advanced squamous cell carcinoma of the head and neck (HNSCC), the rate of treatment failure remains particularly high for patients receiving cisplatin whose tumors have mutations in the TP53 gene. We found that cisplatin treatment of HNSCC cells with mutant TP53 leads to arrest of cells in the G2 phase of the cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.